Breakthrough Therapy Designation is generally granted to a drug when evidences suggest that ... You can see the complete list of today’s Zacks #1 Rank stocks here. In the past 90 days, estimates ...

SeaStar Medical plans to conduct an interim analysis at the trial’s 90-day primary endpoint with the first 100 subjects. Given the current pace of enrollment, the company anticipates a Data Safety ...

As a result, I put NUVL high up on my watch list for the remainder ... Notably, Zidesamtinib has the FDA’s Breakthrough Therapy and Orphan Drug designations. The company also has NVL-655 ...

The table below is a review of notable updates that occurred in December 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

The table below is a review of notable updates that occurred in December 2024 for investigational products in development (not an inclusive list). Click on the ... of hematological malignancies.

We are delighted that QUELIMMUNE is now available to treat severely ill children at yet another prominent academic medical center,” said Tim Varacek, SeaStar Medical Senior Vice President, Commercial ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

First Patient enrolled and treated at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital  Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding ...

Aethlon Medical, Inc. (Nasdaq: AEMD ), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious ...

At Fierce Healthcare, we keep track of all the venture capital being funneled into the health tech and digital health ...